Physician profile
Miriam Fox
NPI 1962885301
$4,494.14
in general payments reported to CMS, 2019-2025
26 companies · $1,719 in 2025
The $1,719 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $359 · 2022: $1,010 · 2023: $771 · 2024: $634 · 2025: $1,719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,409 · Consulting Fee: $500 · Education: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,409.06 |
| Consulting Fee | $500.00 |
| Education | $215.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $592.19 | 2022-2025 | Otezla, Otezla |
| Medimetriks Pharmaceuticals, INC. | $500.00 | 2025 | Neo-Synalar |
| Pfizer INC. | $400.30 | 2021-2024 | |
| Abbvie INC. | $391.63 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $358.95 | 2021-2025 | Winlevi, Absorica Ld |
| Galderma Laboratories, L.P. | $342.90 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Novartis Pharmaceuticals Corporation | $264.63 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $239.73 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $204.87 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Biofrontera INC. | $177.32 | 2022-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Epi Health, LLC | $164.65 | 2021-2022 | |
| Almirall LLC | $139.55 | 2021-2023 | Klisyri |
| Incyte Corporation | $123.32 | 2021-2023 | Opzelura |
| Genzyme Corporation | $100.21 | 2022-2025 | |
| Botanix Sb INC | $80.24 | 2025 | Sofdra |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $75.29 | 2023-2024 | Sotyktu |
| Mayne Pharma Commercial LLC | $66.69 | 2021-2025 | |
| Lilly USA, LLC | $59.24 | 2022-2024 | Olumiant, Taltz |
| Regeneron Healthcare Solutions, INC. | $57.54 | 2021-2025 | Libtayo |
| Convatec INC. | $37.61 | 2025 | |
| Kyowa Kirin, INC. | $32.70 | 2022-2024 | Poteligeo |
| Vyne Pharmaceuticals INC. | $27.28 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.82 | 2022 | |
| Ucb, INC. | $14.05 | 2025 | Bimzelx |
| Leo Pharma INC. | $13.85 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.58 | 2024 | Duobrii, Arazlo, Jublia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miriam Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.